Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 7,866 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 7,866 shares of the stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $37.69, for a total transaction of $296,469.54. Following the transaction, the insider owned 54,645 shares in the company, valued at $2,059,570.05. The trade was a 12.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

• On Thursday, October 22nd, Sarah Gheuens sold 500 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $37.52, for a total transaction of $18,760.00.
• On Wednesday, October 21st, Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $37.53, for a total transaction of $55,882.17.
• On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $30.48, for a total value of $914,400.00.

Agios Pharmaceuticals Stock Performance

Shares of AGIO traded up $0.09 during mid-day trading on Wednesday, reaching $38.12. The company had a trading volume of 912,920 shares, compared to its average volume of 1,055,831. The firm has a 50-day moving average price of $33.57 and a 200 day moving average price of $31.60. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -5.44 and a beta of 0.63.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The firm had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AGIO. Royal Bank Of Canada lifted their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Bank of America raised their target price on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a report on Monday, September 21st. JPMorgan Chase & Co. boosted their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, September 21st. Finally, Citigroup increased their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $41.50.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in shares of Agios Pharmaceuticals by 4.0% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 28,861 shares of the biopharmaceutical company’s stock worth $960,000 after purchasing an additional 1,100 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Agios Pharmaceuticals by 15.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,893 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 1,428 shares during the last quarter. Inspire Investing LLC raised its holdings in Agios Pharmaceuticals by 4.7% in the 3rd quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company’s stock valued at $636,000 after buying an additional 861 shares during the period. Assenagon Asset Management S.A. raised its holdings in Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after buying an additional 1,782,457 shares during the period. Finally, Tidal Investments LLC lifted its position in Agios Pharmaceuticals by 12.0% in the second quarter. Tidal Investments LLC now owns 16,100 shares of the biopharmaceutical company’s stock valued at $597,000 after buying an additional 1,724 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.